Skip to main content
. 2021 Sep 18;7:253. doi: 10.1038/s41420-021-00644-4

Fig. 6. miR-2337 controls the TGF-β1-mediated TGF-β signaling pathway and GC apoptosis.

Fig. 6

A, B miR-2337 activates the TGF-β signaling pathway, and inhibits GC apoptosis. Total SMAD3 (t-SMAD3) levels, phosphorylated SMAD3 (p-SMAD3) levels and the apoptosis rate were assessed in miR-2337-overexpressing GCs, using qRT-PCR and flow cytometry. C, D miR-2337 controls the TGF-β signaling pathway and GCs apoptosis by activating TGF-β1. T-SMAD3 levels, p-SMAD3 levels, and the apoptosis rate were determined in GCs co-treated with SB431542 (an inhibitor of the TGF-β signaling pathway), and miR-2337 mimics, using qRT-PCR and flow cytometry. Data are represented as means ± S.E.M. (n = 3). *p < 0.05.